Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Prostatic Neoplasms"" wg kryterium: Temat


Tytuł :
Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene Alterations.
Autorzy :
Shore N; Carolina Urologic Research Center , Myrtle Beach, South Carolina.
Oliver L; Adelphi Values PROVE , Manchester, UK.
Shui I; Merck & Co.Inc., Kenilworth, New Jersey.
Gayle A; AstraZeneca , Cambridge, UK.
Wong OY; Adelphi Values PROVE , Manchester, UK.
Kim J; Merck & Co.Inc., Kenilworth, New Jersey.
Payne S; AstraZeneca , Cambridge, UK.
Amin S; AstraZeneca , Cambridge, UK.
Ghate S; Merck & Co.Inc., Kenilworth, New Jersey.
Pokaż więcej
Źródło :
The Journal of urology [J Urol] 2021 Apr; Vol. 205 (4), pp. 977-986. Date of Electronic Publication: 2020 Dec 17.
Typ publikacji :
Journal Article; Systematic Review
MeSH Terms :
Recombinational DNA Repair*
Biomarkers, Tumor/*genetics
Prostatic Neoplasms, Castration-Resistant/*epidemiology
Prostatic Neoplasms, Castration-Resistant/*genetics
Circulating Tumor DNA/genetics ; DNA Mutational Analysis ; Disease Progression ; Genetic Predisposition to Disease ; Germ-Line Mutation ; Humans ; Male ; Neoplasm Metastasis ; Prevalence ; Prognosis ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms, Castration-Resistant/pathology
Czasopismo naukowe
Tytuł :
Nuclear overexpression levels of MAGE-A3 predict poor prognosis in patients with prostate cancer.
Autorzy :
Khalvandi A; Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Abolhasani M; Hasheminejad Kidney Center, Iran University of Medical Sciences, Tehran, Iran.; Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran.
Madjd Z; Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran.
Shekarabi M; Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Kourosh-Arami M; Department of Neuroscience, School of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran.
Mohsenzadegan M; Department of Medical Laboratory Science, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran.
Pokaż więcej
Źródło :
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica [APMIS] 2021 Jun; Vol. 129 (6), pp. 291-303. Date of Electronic Publication: 2021 Apr 13.
Typ publikacji :
Journal Article
MeSH Terms :
Antigens, Neoplasm/*biosynthesis
Biomarkers, Tumor/*metabolism
Neoplasm Proteins/*biosynthesis
Prostatic Neoplasms/*pathology
Aged ; Aged, 80 and over ; Antigens, Neoplasm/analysis ; Biomarkers, Tumor/analysis ; Cell Nucleus/metabolism ; Humans ; Male ; Middle Aged ; Neoplasm Proteins/analysis ; Prognosis ; Prostatic Neoplasms/metabolism ; Prostatic Neoplasms/mortality ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Reference-free transcriptome signatures for prostate cancer prognosis.
Autorzy :
Nguyen HTN; Institute for Integrative Biology of the Cell, UMR 9198, CEA, CNRS, Université Paris-Saclay, Gif-Sur-Yvette, France.
Xue H; Institute for Integrative Biology of the Cell, UMR 9198, CEA, CNRS, Université Paris-Saclay, Gif-Sur-Yvette, France.
Firlej V; Institute of Biology, Université Paris Est Creteil, Creteil, Creteil, France.
Ponty Y; LIX CNRS UMR 7161, Ecole Polytechnique, Institut Polytechnique de Paris, Palaiseau, France.
Gallopin M; Institute for Integrative Biology of the Cell, UMR 9198, CEA, CNRS, Université Paris-Saclay, Gif-Sur-Yvette, France.
Gautheret D; Institute for Integrative Biology of the Cell, UMR 9198, CEA, CNRS, Université Paris-Saclay, Gif-Sur-Yvette, France. .
Pokaż więcej
Źródło :
BMC cancer [BMC Cancer] 2021 Apr 12; Vol. 21 (1), pp. 394. Date of Electronic Publication: 2021 Apr 12.
Typ publikacji :
Journal Article
MeSH Terms :
Biomarkers, Tumor*
Transcriptome*
Prostatic Neoplasms/*genetics
Prostatic Neoplasms/*mortality
Algorithms ; Computational Biology/methods ; Gene Expression Profiling ; High-Throughput Nucleotide Sequencing ; Humans ; Male ; Prognosis ; Prostatic Neoplasms/pathology ; Recurrence ; Reproducibility of Results ; Supervised Machine Learning
Czasopismo naukowe
Tytuł :
Clinicopathological features to distinguish malignant solitary fibrous tumors of the prostate from prostatic stromal tumors.
Autorzy :
Xu Y; The Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Zhongshan Road No. 321, Nanjing, 210008, China.; The Department of Pathology, Duke University School of Medicine, Durham, NC, 27710, USA.
Li Z; The Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Zhongshan Road No. 321, Nanjing, 210008, China.
Shi J; The Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Zhongshan Road No. 321, Nanjing, 210008, China.
Fu Y; The Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Zhongshan Road No. 321, Nanjing, 210008, China.
Zhu L; The Department of Medical Imaging, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Zhongshan Road No. 321, Nanjing, 210008, China.
Fan X; The Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Zhongshan Road No. 321, Nanjing, 210008, China.
Foo WC; The Department of Pathology, Duke University School of Medicine, Durham, NC, 27710, USA. .
Pokaż więcej
Źródło :
Virchows Archiv : an international journal of pathology [Virchows Arch] 2021 Apr; Vol. 478 (4), pp. 619-626. Date of Electronic Publication: 2020 Aug 20.
Typ publikacji :
Journal Article
MeSH Terms :
Biomarkers, Tumor/*metabolism
Prostatic Neoplasms/*diagnosis
Prostatic Neoplasms/*pathology
Solitary Fibrous Tumors/*diagnosis
Solitary Fibrous Tumors/*pathology
Adult ; Aged ; Aged, 80 and over ; Diagnosis, Differential ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Phenotype ; Prostatic Neoplasms/metabolism ; Retrospective Studies ; Solitary Fibrous Tumors/metabolism ; Tumor Burden
Czasopismo naukowe
Tytuł :
The FTO m A levels.
Autorzy :
Zhu K; Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. Electronic address: .
Li Y; Department of Paediatrics, Heping Hospital affiliated to Changzhi Medical College, Changzhi 046000, China. Electronic address: .
Xu Y; Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. Electronic address: .
Pokaż więcej
Źródło :
Life sciences [Life Sci] 2021 Apr 15; Vol. 271, pp. 119180. Date of Electronic Publication: 2021 Feb 08.
Typ publikacji :
Journal Article
MeSH Terms :
Adenosine/*analogs & derivatives
Alpha-Ketoglutarate-Dependent Dioxygenase FTO/*biosynthesis
Biomarkers, Tumor/*biosynthesis
Cell Movement/*physiology
Prostatic Neoplasms/*metabolism
Adenosine/antagonists & inhibitors ; Adenosine/biosynthesis ; Aged ; Carcinogenesis/metabolism ; Carcinogenesis/pathology ; Cell Line, Tumor ; Humans ; Male ; Middle Aged ; Neoplasm Invasiveness/pathology ; Prostate/metabolism ; Prostate/pathology ; Prostatic Neoplasms/pathology
Czasopismo naukowe
Tytuł :
Prognostic role of TSPAN1, KIAA1324 and ESRP1 in prostate cancer.
Autorzy :
Stinnesbeck M; Institute of Pathology, University Hospital Bonn, Bonn, Germany.
Kristiansen A; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Ellinger J; Clinic of Urology, University Hospital Bonn, Bonn, Germany.
Hauser S; Clinic of Urology, University Hospital Bonn, Bonn, Germany.
Egevad L; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Tolkach Y; Institute of Pathology, University Hospital Bonn, Bonn, Germany.; Institute of Pathology, University Hospital Cologne, Cologne, Germany.
Kristiansen G; Institute of Pathology, University Hospital Bonn, Bonn, Germany.
Pokaż więcej
Źródło :
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica [APMIS] 2021 Apr; Vol. 129 (4), pp. 204-212. Date of Electronic Publication: 2021 Feb 02.
Typ publikacji :
Journal Article
MeSH Terms :
Biomarkers, Tumor/*genetics
Neoplasm Proteins/*genetics
Prostatic Neoplasms/*genetics
RNA-Binding Proteins/*genetics
Tetraspanins/*genetics
Aged ; Humans ; Male ; Middle Aged ; Prognosis ; Prostatic Neoplasms/pathology
Czasopismo naukowe
Tytuł :
TAp63 and ΔNp63 (p40) in prostate adenocarcinomas: ΔNp63 associates with a basal-like cancer stem cell population but not with metastasis.
Autorzy :
Galoczova M; Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic.
Nenutil R; Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic.
Pokorna Z; Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic.
Vojtesek B; Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic.
Coates PJ; Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic. .
Pokaż więcej
Źródło :
Virchows Archiv : an international journal of pathology [Virchows Arch] 2021 Apr; Vol. 478 (4), pp. 627-636. Date of Electronic Publication: 2020 Oct 10.
Typ publikacji :
Journal Article
MeSH Terms :
Adenocarcinoma/*secondary
Biomarkers, Tumor/*metabolism
Bone Neoplasms/*secondary
Neoplastic Stem Cells/*metabolism
Prostatic Neoplasms/*pathology
Transcription Factors/*metabolism
Tumor Suppressor Proteins/*metabolism
Adenocarcinoma/metabolism ; Adult ; Aged ; Aged, 80 and over ; Bone Neoplasms/metabolism ; Case-Control Studies ; Humans ; Male ; Middle Aged ; Neoplastic Stem Cells/pathology ; Phenotype ; Prostatic Neoplasms/metabolism ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Ephrin-A2 promotes prostate cancer metastasis by enhancing angiogenesis and promoting EMT.
Autorzy :
Zhao Y; Department of Clinical Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, China.; Medical Technology School of Xuzhou Medical University, Xuzhou, 221004, China.
Cai C; Medical Technology School of Xuzhou Medical University, Xuzhou, 221004, China.; Xuzhou Central Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, 221002, China.
Zhang M; Medical Technology School of Xuzhou Medical University, Xuzhou, 221004, China.
Shi L; Medical Technology School of Xuzhou Medical University, Xuzhou, 221004, China.
Wang J; Medical Technology School of Xuzhou Medical University, Xuzhou, 221004, China.
Zhang H; Department of Laboratory Medicine, Affiliated Hospital of Xuzhou Medical University, 99 West Huaihai Road, Xuzhou, 221002, China.
Ma P; Medical Technology School of Xuzhou Medical University, Xuzhou, 221004, China. .; Department of Laboratory Medicine, Affiliated Hospital of Xuzhou Medical University, 99 West Huaihai Road, Xuzhou, 221002, China. .
Li S; Medical Technology School of Xuzhou Medical University, Xuzhou, 221004, China. .; Department of Laboratory Medicine, Affiliated Hospital of Xuzhou Medical University, 99 West Huaihai Road, Xuzhou, 221002, China. .
Pokaż więcej
Źródło :
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2021 Jul; Vol. 147 (7), pp. 2013-2023. Date of Electronic Publication: 2021 Mar 27.
Typ publikacji :
Journal Article
MeSH Terms :
Epithelial-Mesenchymal Transition*
Biomarkers, Tumor/*metabolism
Ephrin-A2/*metabolism
Neovascularization, Pathologic/*pathology
Prostatic Neoplasms/*secondary
Animals ; Apoptosis ; Biomarkers, Tumor/genetics ; Cell Movement ; Cell Proliferation ; Ephrin-A2/genetics ; Gene Expression Regulation, Neoplastic ; Humans ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Neoplasm Metastasis ; Neovascularization, Pathologic/metabolism ; Prostatic Neoplasms/blood supply ; Prostatic Neoplasms/metabolism ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
EGFR as a stable marker of prostate cancer dissemination to bones.
Autorzy :
Nastały P; Laboratory of Translational Oncology, Institute of Medical Biotechnology and Experimental Oncology, Medical University of Gdańsk, Gdańsk, Poland.; FIRC (Italian Foundation for Cancer Research) Institute of Molecular Oncology (IFOM), Milan, Italy.
Stoupiec S; Department of Tumour Biology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Popęda M; Laboratory of Translational Oncology, Institute of Medical Biotechnology and Experimental Oncology, Medical University of Gdańsk, Gdańsk, Poland.
Smentoch J; Laboratory of Translational Oncology, Institute of Medical Biotechnology and Experimental Oncology, Medical University of Gdańsk, Gdańsk, Poland.
Schlomm T; Department of Urology, Charité University Hospital Berlin, Berlin, Germany.
Morrissey C; Department of Urology, University of Washington, Seattle, WA, USA.
Żaczek AJ; Laboratory of Translational Oncology, Institute of Medical Biotechnology and Experimental Oncology, Medical University of Gdańsk, Gdańsk, Poland.
Beyer B; Martini-Clinic, Prostate Cancer Center and Section for Translational Prostate Cancer Research at the Clinic of Urology at University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Tennstedt P; Martini-Clinic, Prostate Cancer Center and Section for Translational Prostate Cancer Research at the Clinic of Urology at University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Graefen M; Martini-Clinic, Prostate Cancer Center and Section for Translational Prostate Cancer Research at the Clinic of Urology at University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Eltze E; Institute of Pathology Saarbruecken-Rastpfuhl, Saarbruecken, Germany.
Maiuri P; FIRC (Italian Foundation for Cancer Research) Institute of Molecular Oncology (IFOM), Milan, Italy.
Semjonow A; Department of Urology, Prostate Center University Clinic Münster, Münster, Germany.
Pantel K; Department of Tumour Biology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Brandt B; University Medical Centre Schleswig-Holstein, Kiel, Germany.
Bednarz-Knoll N; Laboratory of Translational Oncology, Institute of Medical Biotechnology and Experimental Oncology, Medical University of Gdańsk, Gdańsk, Poland. .; Department of Tumour Biology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. .
Pokaż więcej
Źródło :
British journal of cancer [Br J Cancer] 2020 Dec; Vol. 123 (12), pp. 1767-1774. Date of Electronic Publication: 2020 Sep 09.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Biomarkers, Tumor/*metabolism
Bone Neoplasms/*secondary
Neoplastic Cells, Circulating/*metabolism
Prostatic Neoplasms/*pathology
Biomarkers, Tumor/genetics ; Bone Neoplasms/mortality ; Cell Movement ; Collagen Type I/genetics ; Epithelial-Mesenchymal Transition ; ErbB Receptors/genetics ; ErbB Receptors/metabolism ; Feasibility Studies ; Flow Cytometry ; Humans ; Immunohistochemistry ; Male ; Neoplastic Cells, Circulating/pathology ; Prostatic Neoplasms/metabolism ; Prostatic Neoplasms/mortality ; Prostatic Neoplasms, Castration-Resistant/metabolism ; Prostatic Neoplasms, Castration-Resistant/mortality ; Prostatic Neoplasms, Castration-Resistant/pathology ; Vimentin/metabolism
Czasopismo naukowe
Tytuł :
Distinct roles for the RNA-binding protein Staufen1 in prostate cancer.
Autorzy :
Marcellus KA; Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, 451 Smyth Road, Ottawa, Ontario, K1H8M5, Canada.; The Eric J. Poulin Centre for Neuromuscular Diseases, Ottawa, Ontario, Canada.
Crawford Parks TE; Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, 451 Smyth Road, Ottawa, Ontario, K1H8M5, Canada.; The Eric J. Poulin Centre for Neuromuscular Diseases, Ottawa, Ontario, Canada.
Almasi S; Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, 451 Smyth Road, Ottawa, Ontario, K1H8M5, Canada.; The Eric J. Poulin Centre for Neuromuscular Diseases, Ottawa, Ontario, Canada.
Jasmin BJ; Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, 451 Smyth Road, Ottawa, Ontario, K1H8M5, Canada. .; The Eric J. Poulin Centre for Neuromuscular Diseases, Ottawa, Ontario, Canada. .
Pokaż więcej
Źródło :
BMC cancer [BMC Cancer] 2021 Feb 04; Vol. 21 (1), pp. 120. Date of Electronic Publication: 2021 Feb 04.
Typ publikacji :
Journal Article
MeSH Terms :
Gene Expression Regulation, Neoplastic*
Biomarkers, Tumor/*metabolism
Cytoskeletal Proteins/*metabolism
Prostatic Neoplasms/*pathology
RNA-Binding Proteins/*metabolism
Apoptosis ; Biomarkers, Tumor/genetics ; Cell Cycle ; Cell Movement ; Cell Proliferation ; Cytoskeletal Proteins/genetics ; Humans ; Male ; Neoplasm Invasiveness ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms/metabolism ; RNA-Binding Proteins/genetics ; Tumor Cells, Cultured
Czasopismo naukowe
Tytuł :
A Novel cytarabine analog evokes synthetic lethality by targeting MK2 in p53-deficient cancer cells.
Autorzy :
Song J; College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea.
Yu J; College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea.
Jeong LS; College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea.
Lee SK; College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea. Electronic address: .
Pokaż więcej
Źródło :
Cancer letters [Cancer Lett] 2021 Jan 28; Vol. 497, pp. 54-65. Date of Electronic Publication: 2020 Oct 16.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Synthetic Lethal Mutations*
Biomarkers, Tumor/*metabolism
Cytarabine/*analogs & derivatives
Gene Expression Regulation, Neoplastic/*drug effects
Intracellular Signaling Peptides and Proteins/*metabolism
Prostatic Neoplasms/*drug therapy
Protein-Serine-Threonine Kinases/*metabolism
Tumor Suppressor Protein p53/*metabolism
Animals ; Antimetabolites, Antineoplastic/chemistry ; Antimetabolites, Antineoplastic/pharmacology ; Apoptosis ; Biomarkers, Tumor/genetics ; Cell Cycle Checkpoints ; Cell Movement ; Cell Proliferation ; Cytarabine/pharmacology ; DNA Damage ; DNA Repair ; Humans ; Intracellular Signaling Peptides and Proteins/genetics ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Prostatic Neoplasms/metabolism ; Prostatic Neoplasms/pathology ; Protein-Serine-Threonine Kinases/genetics ; Tumor Cells, Cultured ; Tumor Suppressor Protein p53/genetics ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment.
Autorzy :
Dhimolea E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. .; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
de Matos Simoes R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
Kansara D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Weng X; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Sharma S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Awate P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Liu Z; Department of Biomedical Engineering, Tufts University, Medford, Massachusetts.
Gao D; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York.
Mitsiades N; Baylor College of Medicine, Houston, Texas.
Schwab JH; Harvard Medical School, Boston, Massachusetts.; Massachusetts General Hospital, Boston, Massachusetts.
Chen Y; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York.
Jeselsohn R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.
Culhane AC; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute & Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Brown M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.
Georgakoudi I; Department of Biomedical Engineering, Tufts University, Medford, Massachusetts.
Mitsiades CS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. .; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
Pokaż więcej
Źródło :
Cancer research [Cancer Res] 2021 Jan 15; Vol. 81 (2), pp. 371-383. Date of Electronic Publication: 2020 Aug 28.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Drug Resistance, Neoplasm*
Antineoplastic Agents, Hormonal/*pharmacology
Biomarkers, Tumor/*metabolism
Bone Neoplasms/*drug therapy
Breast Neoplasms/*drug therapy
Gene Expression Regulation, Neoplastic/*drug effects
Prostatic Neoplasms/*drug therapy
Animals ; Apoptosis ; Biomarkers, Tumor/genetics ; Bone Neoplasms/metabolism ; Bone Neoplasms/secondary ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; Cell Proliferation ; Female ; Humans ; Male ; Mice ; Mice, Nude ; Prostatic Neoplasms/metabolism ; Prostatic Neoplasms/pathology ; Receptors, Estrogen/metabolism ; Tumor Cells, Cultured ; Tumor Microenvironment ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Identification of a novel six autophagy-related genes signature for the prognostic and a miRNA-related autophagy predictor for anti-PD-1 therapy responses in prostate cancer.
Autorzy :
Wu L; Department of Oncology, Zhuhai People's Hospital (Zhuhai Hospital affiliated with Jinan University), Zhuhai, Guangdong Province, P. R. China.
Quan W; Department of Oncology, Zhuhai People's Hospital (Zhuhai Hospital affiliated with Jinan University), Zhuhai, Guangdong Province, P. R. China.
Yue G; Zunyi Medical University, Zunyi, Guizhou Province, P. R. China.
Luo Q; Department of Oncology, Affiliated Zhuhai Hospital, Southern Medical University, Zhuhai, Guangdong Province, P. R. China.
Peng D; Department of Oncology, Zhuhai People's Hospital (Zhuhai Hospital affiliated with Jinan University), Zhuhai, Guangdong Province, P. R. China.
Pan Y; Department of Oncology, Zhuhai People's Hospital (Zhuhai Hospital affiliated with Jinan University), Zhuhai, Guangdong Province, P. R. China. .
Zhang G; Department of Oncology, Zhuhai People's Hospital (Zhuhai Hospital affiliated with Jinan University), Zhuhai, Guangdong Province, P. R. China. .; Zunyi Medical University, Zunyi, Guizhou Province, P. R. China. .
Pokaż więcej
Źródło :
BMC cancer [BMC Cancer] 2021 Jan 05; Vol. 21 (1), pp. 15. Date of Electronic Publication: 2021 Jan 05.
Typ publikacji :
Journal Article
MeSH Terms :
Autophagy*
Antineoplastic Agents, Immunological/*therapeutic use
Biomarkers, Tumor/*genetics
MicroRNAs/*genetics
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Prostatic Neoplasms/*pathology
RNA, Messenger/*metabolism
Gene Expression Regulation, Neoplastic ; Gene Regulatory Networks ; Humans ; Male ; Prognosis ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/genetics ; RNA, Messenger/genetics ; Survival Rate ; Transcriptome
Czasopismo naukowe
Tytuł :
Transcriptional Repression of SIRT3 Potentiates Mitochondrial Aconitase Activation to Drive Aggressive Prostate Cancer to the Bone.
Autorzy :
Sawant Dessai A; Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Dominguez MP; Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Chen UI; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.
Hasper J; Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Prechtl C; Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Yu C; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.
Katsuta E; Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Dai T; Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Zhu B; Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Jung SY; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.; Department of Biochemistry, Baylor College of Medicine, Houston, Texas.
Putluri N; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.
Takabe K; Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Zhang XH; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.
O'Malley BW; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.
Dasgupta S; Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, New York. .
Pokaż więcej
Źródło :
Cancer research [Cancer Res] 2021 Jan 01; Vol. 81 (1), pp. 50-63. Date of Electronic Publication: 2020 Oct 28.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Gene Expression Regulation, Neoplastic*
Aconitate Hydratase/*metabolism
Biomarkers, Tumor/*metabolism
Bone Neoplasms/*secondary
Mitochondria/*enzymology
Prostatic Neoplasms/*pathology
Sirtuin 3/*metabolism
Aconitate Hydratase/genetics ; Animals ; Apoptosis ; Biomarkers, Tumor/genetics ; Bone Neoplasms/genetics ; Bone Neoplasms/metabolism ; Cell Proliferation ; Humans ; Male ; Mice ; Mice, Nude ; Nuclear Receptor Coactivator 3/genetics ; Nuclear Receptor Coactivator 3/metabolism ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms/metabolism ; Receptors, Androgen/genetics ; Receptors, Androgen/metabolism ; Sirtuin 3/genetics ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Aberrant GATA3 Staining in Prostatic Adenocarcinoma: A Potential Diagnostic Pitfall.
Autorzy :
McDonald TM; Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD.
Epstein JI
Pokaż więcej
Źródło :
The American journal of surgical pathology [Am J Surg Pathol] 2021 Mar 01; Vol. 45 (3), pp. 341-346.
Typ publikacji :
Journal Article
MeSH Terms :
Immunohistochemistry*
Adenocarcinoma/*chemistry
Biomarkers, Tumor/*analysis
GATA3 Transcription Factor/*analysis
Prostatic Neoplasms/*chemistry
Adenocarcinoma/pathology ; Cell Differentiation ; Databases, Factual ; Diagnosis, Differential ; Humans ; Male ; Neoplasm Grading ; Predictive Value of Tests ; Prostatic Neoplasms/pathology ; Reproducibility of Results
Czasopismo naukowe
Tytuł :
Prostate Cancer Peripheral Blood NK Cells Show Enhanced CD9, CD49a, CXCR4, CXCL8, MMP-9 Production and Secrete Monocyte-Recruiting and Polarizing Factors.
Autorzy :
Gallazzi M; Laboratory of Immunology and General Pathology, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy.
Baci D; Laboratory of Immunology and General Pathology, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy.
Mortara L; Laboratory of Immunology and General Pathology, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy.
Bosi A; Laboratory of Pharmacology, Department of Medicine and Surgery, University of Insubria, Varese, Italy.
Buono G; Unit of Immunology, IRCCS MultiMedica, Milan, Italy.
Naselli A; Unit of Urology, San Giuseppe Hospital, IRCCS MultiMedica, Milan, Italy.
Guarneri A; Unit of Urology, San Giuseppe Hospital, IRCCS MultiMedica, Milan, Italy.
Dehò F; S.C. of Urology, ASST Settelaghi, Ospedale di Circolo e Fondazione Macchi, Varese, Italy.
Capogrosso P; S.C. of Urology, ASST Settelaghi, Ospedale di Circolo e Fondazione Macchi, Varese, Italy.
Albini A; Laboratory of Vascular Biology and Angiogenesis, IRCCS MultiMedica, Milano, Italy.
Noonan DM; Laboratory of Immunology and General Pathology, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy.; Laboratory of Vascular Biology and Angiogenesis, IRCCS MultiMedica, Milano, Italy.
Bruno A; Unit of Immunology, IRCCS MultiMedica, Milan, Italy.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2021 Jan 25; Vol. 11, pp. 586126. Date of Electronic Publication: 2021 Jan 25 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Adenocarcinoma/*immunology
Biomarkers, Tumor/*immunology
Killer Cells, Natural/*immunology
Prostatic Neoplasms/*immunology
Adenocarcinoma/blood ; Biomarkers, Tumor/blood ; Chemotaxis, Leukocyte/immunology ; Cytokines/metabolism ; Female ; Humans ; Lymphocyte Subsets/immunology ; Macrophages/immunology ; Male ; Prostatic Neoplasms/blood
Czasopismo naukowe
Tytuł :
Prostate Cancer Diagnosis in the Clinic Using an 8-Protein Biomarker Panel.
Autorzy :
Jones AL; Department of Chemistry, University of Connecticut, 55 North Eagleville Road, Storrs, Connecticut 06269, United States.
Dhanapala L; Department of Chemistry, University of Connecticut, 55 North Eagleville Road, Storrs, Connecticut 06269, United States.
Baldo TA; Department of Chemistry, Federal University of São Carlos, São Carlos 13565-905, São Paulo, Brazil.
Sharafeldin M; Department of Chemistry, University of Connecticut, 55 North Eagleville Road, Storrs, Connecticut 06269, United States.
Krause CE; Department of Chemistry, University of Hartford, 200 Bloomfield Avenue, West Hartford, Connecticut 06117, United States.
Shen M; Department of Chemistry, University of Connecticut, 55 North Eagleville Road, Storrs, Connecticut 06269, United States.
Moghaddam S; School of Mathematical Sciences, University College Cork, Cork T12YT20, Ireland.
Faria RC; Department of Chemistry, Federal University of São Carlos, São Carlos 13565-905, São Paulo, Brazil.
Dey DK; Department of Statistics, University of Connecticut, 215 Glenbrook Road, Storrs, Connecticut 06269, United States.
Watson RW; Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland.; UCD School of Medicine and Medical Science, University College Dublin, Dublin 4, Ireland.
Andrawis R; Department of Urology, George Washington University, 2300 I Street, NW, Washington, Washington, D.C. 20037, United States.
Lee NH; Department of Pharmacology and Physiology, George Washington University, 2300 I Street, NW, Washington, Washington, D.C. 20037, United States.; GW Cancer Center, 800 22nd Street, NW, Washington, Washington, D.C. 20052, United States.
Rusling JF; Department of Chemistry, University of Connecticut, 55 North Eagleville Road, Storrs, Connecticut 06269, United States.; School of Chemistry, National University of Ireland Galway, University Road, Galway H91 CF50, Ireland.; Institute of Materials Science, University of Connecticut, 97 N. Eagleville Road, Storrs, Connecticut 06269, United States.; Department of Surgery, UConn Health Center, Farmington, Connecticut 06232, United States.
Pokaż więcej
Źródło :
Analytical chemistry [Anal Chem] 2021 Jan 19; Vol. 93 (2), pp. 1059-1067. Date of Electronic Publication: 2020 Dec 08.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunoassay*
Microfluidic Analytical Techniques*
Biomarkers, Tumor/*blood
Neoplasm Proteins/*blood
Prostatic Neoplasms/*diagnosis
Humans ; Male ; Prostatic Neoplasms/blood
Czasopismo naukowe
Tytuł :
Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression.
Autorzy :
Chen S; Department of Urology, Shanghai Changhai Hospital, Shanghai, P. R. China.; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Zhu G; Department of Urology, Shanghai Changhai Hospital, Shanghai, P. R. China.; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Urology Institute of Shenzhen University, The Third Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, P. R. China.; Department of Urological Surgery, The Affiliated Luohu Hospital of Shenzhen University, Shenzhen University, Shenzhen, P. R. China.
Yang Y; Department of Urology, Shanghai Changhai Hospital, Shanghai, P. R. China.
Wang F; Department of Urology, Shanghai Changhai Hospital, Shanghai, P. R. China.
Xiao YT; Department of Urology, Shanghai Changhai Hospital, Shanghai, P. R. China.
Zhang N; East China Normal University, Shanghai, P. R. China.
Bian X; Cancer Institute, Shanghai Urological Cancer Institute, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, P. R. China.
Zhu Y; Department of Urology, Shanghai Changhai Hospital, Shanghai, P. R. China.
Yu Y; Department of Urology, Shanghai Changhai Hospital, Shanghai, P. R. China.
Liu F; Department of Urology, Cancer Hospital, Chinese Academy of Medical Sciences, Shanghai, P. R. China.
Dong K; Department of Urology, Shanghai Changhai Hospital, Shanghai, P. R. China.
Mariscal J; Department of Surgery, Division of Cancer Biology and Therapeutics, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Liu Y; Department of Laboratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, P. R. China.
Soares F; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Loo Yau H; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
Zhang B; Novel Bioinformatics Co., Ltd, Shanghai, P. R. China.
Chen W; Novel Bioinformatics Co., Ltd, Shanghai, P. R. China.
Wang C; Novel Bioinformatics Co., Ltd, Shanghai, P. R. China.
Chen D; Novel Bioinformatics Co., Ltd, Shanghai, P. R. China.
Guo Q; Novel Bioinformatics Co., Ltd, Shanghai, P. R. China.
Yi Z; East China Normal University, Shanghai, P. R. China.
Liu M; East China Normal University, Shanghai, P. R. China.
Fraser M; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
De Carvalho DD; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
Boutros PC; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.; Department of Human Genetics, University of California Los Angeles, Los Angeles, CA, USA.; Department of Urology, University of California Los Angeles, Los Angeles, CA, USA.; Jonsson Comprehensive Cancer Centre, University of California Los Angeles, Los Angeles, USA.; Institute for Precision Health, University of California Los Angeles, Los Angeles, CA, USA.; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada.
Di Vizio D; Department of Surgery, Division of Cancer Biology and Therapeutics, Cedars-Sinai Medical Center, Los Angeles, CA, USA.; Samuel Oschin Comprehensive Cancer Institute, Division of Cancer Biology and Therapeutics, Cedars-Sinai Medical Center, Los Angeles, CA, USA.; Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.; Department of Biomedical Sciences, Division of Cancer Biology and Therapeutics, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Jiang Z; Department of Pathology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, P. R. China.
van der Kwast T; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Berlin A; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
Wu S; Urology Institute of Shenzhen University, The Third Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, P. R. China.; Department of Urological Surgery, The Affiliated Luohu Hospital of Shenzhen University, Shenzhen University, Shenzhen, P. R. China.
Wang J; Cancer Institute, Shanghai Urological Cancer Institute, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, P. R. China. .
He HH; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. .; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada. .
Ren S; Department of Urology, Shanghai Changhai Hospital, Shanghai, P. R. China. .
Pokaż więcej
Źródło :
Nature cell biology [Nat Cell Biol] 2021 Jan; Vol. 23 (1), pp. 87-98. Date of Electronic Publication: 2021 Jan 08.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Gene Expression Regulation, Neoplastic*
Transcriptome*
Tumor Microenvironment*
Biomarkers, Tumor/*genetics
Cell Lineage/*genetics
Prostatic Neoplasms/*pathology
Single-Cell Analysis/*methods
Cell Survival ; Computational Biology ; Disease Progression ; Endothelial Cells/metabolism ; Endothelial Cells/pathology ; Epithelial Cells/metabolism ; Epithelial Cells/pathology ; Fibroblasts/metabolism ; Fibroblasts/pathology ; Humans ; Male ; Prostatic Neoplasms/genetics
Czasopismo naukowe
Tytuł :
Quantitative MRI: Defining repeatability, reproducibility and accuracy for prostate cancer imaging biomarker development.
Autorzy :
Wang Y; Institute of Medical Physics, School of Physics, Faculty of Science, The University of Sydney, Sydney, NSW, Australia; Ingham Institute for Applied Medical Research, Liverpool, NSW, Australia. Electronic address: .
Tadimalla S; Institute of Medical Physics, School of Physics, Faculty of Science, The University of Sydney, Sydney, NSW, Australia.
Rai R; Ingham Institute for Applied Medical Research, Liverpool, NSW, Australia; Liverpool and Macarthur Cancer Therapy Centre, Liverpool Hospital, Liverpool, NSW, Australia; South Western Sydney Clinical School, University of New South Wales, Liverpool, NSW, Australia.
Goodwin J; Department of Radiation Oncology, Calvary Mater Hospital, Waratah, NSW, Australia.
Foster S; Discipline of Medical Imaging Science, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Radiology Department, Westmead Hospital, Westmead, NSW, Australia.
Liney G; Ingham Institute for Applied Medical Research, Liverpool, NSW, Australia; Liverpool and Macarthur Cancer Therapy Centre, Liverpool Hospital, Liverpool, NSW, Australia; South Western Sydney Clinical School, University of New South Wales, Liverpool, NSW, Australia.
Holloway L; Ingham Institute for Applied Medical Research, Liverpool, NSW, Australia; Liverpool and Macarthur Cancer Therapy Centre, Liverpool Hospital, Liverpool, NSW, Australia; South Western Sydney Clinical School, University of New South Wales, Liverpool, NSW, Australia.
Haworth A; Institute of Medical Physics, School of Physics, Faculty of Science, The University of Sydney, Sydney, NSW, Australia.
Pokaż więcej
Źródło :
Magnetic resonance imaging [Magn Reson Imaging] 2021 Apr; Vol. 77, pp. 169-179. Date of Electronic Publication: 2021 Jan 01.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Biomarkers, Tumor/*metabolism
Magnetic Resonance Imaging/*methods
Prostatic Neoplasms/*diagnostic imaging
Prostatic Neoplasms/*metabolism
Humans ; Male ; Phantoms, Imaging ; Reproducibility of Results
Czasopismo naukowe
Tytuł :
A four-gene signature associated with clinical features can better predict prognosis in prostate cancer.
Autorzy :
Yuan P; Department of Urology Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Ling L; Department of Urology Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Fan Q; Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Gao X; Department of Urology Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Sun T; Department of Urology Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Miao J; Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yuan X; Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Liu J; Department of Urology Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Liu B; Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Pokaż więcej
Źródło :
Cancer medicine [Cancer Med] 2020 Nov; Vol. 9 (21), pp. 8202-8215. Date of Electronic Publication: 2020 Sep 13.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Validation Study
MeSH Terms :
Biomarkers, Tumor/*genetics
Prostatic Neoplasms/*genetics
Prostatic Neoplasms/*pathology
3-Oxo-5-alpha-Steroid 4-Dehydrogenase/genetics ; Androgen-Binding Protein/genetics ; Case-Control Studies ; Databases, Genetic ; Enhancer of Zeste Homolog 2 Protein/genetics ; Humans ; Kaplan-Meier Estimate ; Male ; Membrane Proteins/genetics ; Neoplasm Grading ; Neoplasm Staging ; Prognosis ; Proportional Hazards Models ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms/blood ; Prostatic Neoplasms/mortality ; ROC Curve ; Risk Factors ; Survival Rate ; Transcriptome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies